PhD, PhD

Global Neurodegeneration Translator

Brief Bio:

An accomplished biochemist, Dr. Lewis studies neurodegeneration, chromosome structure and function, gene regulation, and protein folding. As CEO and co-founder of Rosetta Therapeutics, he is creating new matter to find a cure for neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s diseases. Dr. Lewis is a global educator. He has been an academic leader and faculty member at U of T since 1974. He served as Associate Vice President, Research and Innovation specializing in Global Research Partnerships from 2010 until 2016. Prior to that he served as Vice Dean of Research and International Relations in the Faculty of Medicine for seven years.

Research Interests:

Research interests include neurodegeneration; the structure and function of chromosomes with specific reference to gene regulation; and protein folding.


Rosetta Therapeutics


"The TRP really speaks to the patient-centred approach to research.”

 - Connie Putterman, Parent Advocate, Cohort 2017